CA3198895A1 - Novel anti-cd47 antibodies and uses thereof - Google Patents

Novel anti-cd47 antibodies and uses thereof

Info

Publication number
CA3198895A1
CA3198895A1 CA3198895A CA3198895A CA3198895A1 CA 3198895 A1 CA3198895 A1 CA 3198895A1 CA 3198895 A CA3198895 A CA 3198895A CA 3198895 A CA3198895 A CA 3198895A CA 3198895 A1 CA3198895 A1 CA 3198895A1
Authority
CA
Canada
Prior art keywords
antibody
cell
cancer
seq
immunologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3198895A
Other languages
English (en)
French (fr)
Inventor
Zhengyi WANG
Wei Cao
Bingshi GUO
Cong XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TJ Biopharma (Shanghai) Co Ltd
Original Assignee
I-Mab Biopharma US Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I-Mab Biopharma US Ltd filed Critical I-Mab Biopharma US Ltd
Publication of CA3198895A1 publication Critical patent/CA3198895A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3198895A 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof Pending CA3198895A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020120869 2020-10-14
CNPCT/CN2020/120869 2020-10-14
CNPCT/CN2020/122188 2020-10-20
CN2020122188 2020-10-20
PCT/CN2021/123892 WO2022078465A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3198895A1 true CA3198895A1 (en) 2022-04-21

Family

ID=81207683

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3198895A Pending CA3198895A1 (en) 2020-10-14 2021-10-14 Novel anti-cd47 antibodies and uses thereof

Country Status (12)

Country Link
US (1) US20230399400A1 (cg-RX-API-DMAC7.html)
EP (1) EP4229088A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023546277A (cg-RX-API-DMAC7.html)
KR (1) KR20230114745A (cg-RX-API-DMAC7.html)
CN (1) CN116348601A (cg-RX-API-DMAC7.html)
AU (1) AU2021360633A1 (cg-RX-API-DMAC7.html)
CA (1) CA3198895A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023005611A2 (cg-RX-API-DMAC7.html)
IL (1) IL302112A (cg-RX-API-DMAC7.html)
MX (1) MX2023004223A (cg-RX-API-DMAC7.html)
TW (1) TW202229351A (cg-RX-API-DMAC7.html)
WO (1) WO2022078465A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200140565A1 (en) 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200140565A1 (en) * 2016-10-20 2020-05-07 I-Mab Novel cd47 monoclonal antibodies and uses thereof
KR102366853B1 (ko) * 2017-11-10 2022-02-23 아이-맵 바이오파마 유에스 리미티드 Cd47 항체 및 사이토카인을 포함하는 융합 단백질
WO2020036977A1 (en) * 2018-08-13 2020-02-20 Arch Oncology, Inc. Therapeutic cd47 antibodies
AU2019370754A1 (en) * 2018-10-31 2021-02-04 I-Mab Biopharma Us Limited Novel CD47 antibodies and methods of using same
CN110582515A (zh) * 2018-11-12 2019-12-17 天境生物科技(上海)有限公司 包含cd47抗体和细胞因子的融合蛋白

Also Published As

Publication number Publication date
TW202229351A (zh) 2022-08-01
EP4229088A1 (en) 2023-08-23
CO2023005611A2 (es) 2023-05-29
AU2021360633A1 (en) 2023-06-15
US20230399400A1 (en) 2023-12-14
WO2022078465A1 (en) 2022-04-21
KR20230114745A (ko) 2023-08-01
JP2023546277A (ja) 2023-11-01
AU2021360633A9 (en) 2025-01-09
CN116348601A (zh) 2023-06-27
MX2023004223A (es) 2023-08-03
IL302112A (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US11485782B2 (en) Anti-claudin 18.2 antibodies
RU2571224C2 (ru) Гуманизированные антитела против axl
CN114981303B (zh) 人源化抗Claudin18.2(CLDN18.2)抗体
CN117545779B (zh) 抗ctla-4抗体的用途
MD3535298T2 (ro) Anticorpi ai PD-1 și utilizări ale acestora
JP2019031552A (ja) Pd−1系結合アンタゴニストおよび抗gpc3抗体を使用して癌を治療する方法
RS60305B1 (sr) Agensi koji vezuju cd123 i njihove upotrebe
WO2011155579A1 (ja) 抗Trop-2抗体
CN117616123A (zh) 抗ctla-4抗体
CN118126180A (zh) 抗cd3抗体和包含所述抗体的分子
WO2022078465A1 (en) Novel anti-cd47 antibodies and uses thereof
US12071478B2 (en) Methods for treating autoimmune diseases incorporating an anti-LAG3 antibody
EP4097143A1 (en) Anti-müllerian hormone receptor 2 antibodies and methods of use
WO2025119313A1 (en) Novel anti-cd47 antibodies and uses thereof
HK40091237A (en) Novel anti-cd47 antibodies and uses thereof
HK40120864A (zh) 抗ctla-4抗体的用途
HK40099253B (en) Use of anti-ctla-4 antibody
HK40034257A (en) Anti-claudin 18.2 antibodies
HK40034257B (en) Anti-claudin 18.2 antibodies
HK40014200A (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
HK40014200B (en) Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250818

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251020

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251230

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260414

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260428